Skip to content

Comparing efficacy of Rivaroxaban versus Warfarin on carotid plaque

Comparing efficacy of Rivaroxaban versus Warfarin on carotid plaque in NVAF patients

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190729044372N1
Enrollment
60
Registered
2019-09-01
Start date
2019-03-07
Completion date
Unknown
Last updated
2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke. Cerebrovascular disease, unspecified

Interventions

Intervention 1: Intervention group: In this group, 30 patients are treated with Rivaroxaban based on GFR for 6 months.patients undergo Color Doppler ultrasound At baseline and after 6 months. Interven

Sponsors

Kermanshah University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Non -valve artrial fibrillation with stroke or TIA or IF<30% Not taking Asprin Lack of kidney and liver diseases and other specific disease

Exclusion criteria

Exclusion criteria: Having a heart valve disorder Taking Asprin

Design outcomes

Primary

MeasureTime frame
Carotid plaque size. Timepoint: Baseline and 6 months later. Method of measurement: Bilateral carotid artery color Doppler ultrasound.;Internal and common carotid stenosis grade. Timepoint: Baseline and 6 months later. Method of measurement: Bilateral carotid artery color Doppler ultrasound.;Create new carotid artery plaque. Timepoint: Baseline and 6 months later. Method of measurement: Bilateral carotid artery color Doppler ultrasound.

Secondary

MeasureTime frame
Brain stroke. Timepoint: At baseline and 6 Months later. Method of measurement: Bilateral carotid artery color Doppler ultrasound.;Probability of recurrence of stroke. Timepoint: At baseline and 6 Months later. Method of measurement: Bilateral carotid artery color Doppler ultrasound.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLeila Afsharhezarkhani

Kermanshah University of Medical Sciences

Lafsharh@kums.ac.ir+98 21 8670 5503

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026